Rosalind Advisors, Inc. 13F holdings
Rosalind Advisors, Inc. reported 29 positions with a total reported value of $266.2M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: DCTH DELCATH SYSTEMS, INC. (15.6%), FENC FENNEC PHARMACEUTICALS INC (12.9%), XERS XERIS BIOPHARMA HOLDINGS INC (8.7%), SVRA SAVARA INC (7.4%), VSTM VERASTEM INC (5.7%). Against 2026-03-31 it opened 3 new positions and exited 6. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Rosalind Advisors, Inc. files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 29 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| DCTH DELCATH SYSTEMS, INC. | 3,300,389 | $41.6M | 15.6% |
| FENC FENNEC PHARMACEUTICALS INC | 3,188,001 | $34.3M | 12.9% |
| XERS XERIS BIOPHARMA HOLDINGS INC | 2,908,981 | $23.0M | 8.7% |
| SVRA SAVARA INC | 3,178,121 | $19.6M | 7.4% |
| VSTM VERASTEM INC | 3,986,509 | $15.2M | 5.7% |
| XFOR X4 PHARMACEUTICALS INC | 3,214,766 | $15.0M | 5.6% |
| EYPT EYEPOINT PHARMACEUTICALS INC | 988,230 | $14.1M | 5.3% |
| CYBIN INC | 1,956,814 | $12.9M | 4.9% |
| VOR VOR BIOPHARMA INC | 648,600 | $11.9M | 4.5% |
| PCVX VAXCYTE INC | 200,000 | $11.6M | 4.4% |
| MDWD MEDIWOUND LTD | 749,054 | $11.0M | 4.1% |
| CLDX CELLDEX THERAPEUTICS INC | 200,000 | $7.4M | 2.8% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 721,504 | $7.2M | 2.7% |
| PROF PROFOUND MEDICAL CORP | 828,118 | $5.5M | 2.1% |
| TLPH TALPHERA INC | 5,169,501 | $5.3M | 2.0% |
| AVIR ATEA PHARMACEUTICALS INC | 1,070,550 | $5.0M | 1.9% |
| MYO MYOMO INC | 3,637,886 | $3.8M | 1.4% |
| OVID OVID THERAPEUTICS INC | 1,107,994 | $3.0M | 1.1% |
| NRXS NEURAXIS INC | 508,055 | $3.0M | 1.1% |
| ABVX ABIVAX SA | 20,869 | $2.8M | 1.0% |
| NSPR INSPIREMD INC | 3,905,743 | $2.7M | 1.0% |
| RGNT REGENTIS BIOMATERIALS LTD | 701,685 | $2.5M | 0.9% |
| PYPD POLYPID LTD | 389,455 | $2.0M | 0.7% |
| BFRI BIOFRONTERA INC | 1,275,609 | $1.2M | 0.5% |
| KURA KURA ONCOLOGY INC | 100,000 | $1.1M | 0.4% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 3 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 6 in all · reported value as of 2026-03-31
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| VSTM VERASTEM INC | 2,138,475 | 3,986,509 | +86.4% | $15.2M |
| FENC FENNEC PHARMACEUTICALS INC | 2,908,201 | 3,188,001 | +9.6% | $34.3M |
| CYBIN INC | 1,531,814 | 1,956,814 | +27.7% | $12.9M |
| TLPH TALPHERA INC | 3,353,916 | 5,169,501 | +54.1% | $5.3M |
| RGNT REGENTIS BIOMATERIALS LTD | 251,510 | 701,685 | +179.0% | $2.5M |
| NRXS NEURAXIS INC | 286,138 | 508,055 | +77.6% | $3.0M |
| BFRI BIOFRONTERA INC | 1,163,962 | 1,275,609 | +9.6% | $1.2M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| PCVX VAXCYTE INC | 290,000 | 200,000 | -31.0% | $11.6M |
| CLDX CELLDEX THERAPEUTICS INC | 330,000 | 200,000 | -39.4% | $7.4M |
| XERS XERIS BIOPHARMA HOLDINGS INC | 3,231,700 | 2,908,981 | -10.0% | $23.0M |
| BCRX BIOCRYST PHARMACEUTICALS INC | 923,057 | 721,504 | -21.8% | $7.2M |
| OKUR ONKURE THERAPEUTICS INC | 443,763 | 150,000 | -66.2% | $684.0K |
| PYPD POLYPID LTD | 597,926 | 389,455 | -34.9% | $2.0M |
| VOR VOR BIOPHARMA INC | 700,000 | 648,600 | -7.3% | $11.9M |
| EYPT EYEPOINT PHARMACEUTICALS INC | 1,036,737 | 988,230 | -4.7% | $14.1M |
| AVIR ATEA PHARMACEUTICALS INC | 1,171,855 | 1,070,550 | -8.6% | $5.0M |
| MYO MYOMO INC | 3,847,272 | 3,637,886 | -5.4% | $3.8M |
| SVRA SAVARA INC | 3,203,721 | 3,178,121 | -0.8% | $19.6M |
CIK 1622627 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
